WELIREG

This brand name is authorized in Canada, Israel, United Kingdom, United States

Active ingredients

The drug WELIREG contains one active pharmaceutical ingredient (API):

1 Belzutifan UNII 7K28NB895L - BELZUTIFAN

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). Belzutifan binds to HIF-2α, and in conditions of hypoxia or impairment of VHL protein function, belzutifan blocks the HIF-2α-HIF-1β interaction, leading to reduced transcription and expression of HIF-2α target genes. In vivo, belzutifan demonstrated anti-tumor activity in mouse xenograft models of renal cell carcinoma. Read about Belzutifan

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
WELIREG Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX74		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX74

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02528908
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9270
Country: US	FDA, National Drug Code	Identifier(s): 0006-5331